PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
The WAVEsystem with the WAVEcontrol 4.0 embedded
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
Syngene's collaboration with Zoetis started in 2011
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Subscribe To Our Newsletter & Stay Updated
